Reuters logo
BRIEF-Realm Therapeutics Announces First Patient Dosed In Phase 2 Study Of PR022
December 5, 2017 / 12:16 PM / in 8 days

BRIEF-Realm Therapeutics Announces First Patient Dosed In Phase 2 Study Of PR022

Dec 5 (Reuters) - Realm Therapeutics Plc:

* REALM THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN PHASE 2 STUDY OF PR022 FOR THE TREATMENT OF ATOPIC DERMATITIS

* REALM THERAPEUTICS - PHASE 2 STUDY OF PR022 TRIAL IS BEING CONDUCTED IN UNITED STATES AND TOP LINE DATA IS EXPECTED IN Q3 2018 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below